Buscopan - side effects
in [IBS]
|
From: MD on 7 Nov 2005 11:23 I have recently been prescribed Buscopan 10mg for my spasms but had unpleasant side effects (tingling, feeling spaced out etc) after the first time I took it (at night). Will they go away when the body gets used to the pills or do I need to ask my doctor for an alternative? I will only take them infrequently.
From: dejanvukos71 on 13 Nov 2005 09:31 Hello MD, have you,maybe,tried drug called Duspatalin,especially developed for IBS sufferers,ie. for the spasms?Maybe you should try to talk to your doc about it...they say it is highly effective...it is manufactured by the Solvay pharmaceutical company. Best wishes, Danny MD wrote: > I have recently been prescribed Buscopan 10mg for my spasms but had > unpleasant side effects (tingling, feeling spaced out etc) after the first > time I took it (at night). Will they go away when the body gets used to the > pills or do I need to ask my doctor for an alternative? I will only take > them infrequently.
From: MD on 17 Nov 2005 03:53 I live in the UK. This does not appear to be available here under that name. Any ideas if it does and what its name might be? <dejanvukos71(a)yahoo.com> wrote in message news:1131892271.371132.300390(a)f14g2000cwb.googlegroups.com... > Hello MD, > > have you,maybe,tried drug called Duspatalin,especially developed for > IBS sufferers,ie. for the spasms?Maybe you should try to talk to your > doc about it...they say it is highly effective...it is manufactured by > the Solvay pharmaceutical company. > Best wishes, > Danny > MD wrote: > > I have recently been prescribed Buscopan 10mg for my spasms but had > > unpleasant side effects (tingling, feeling spaced out etc) after the first > > time I took it (at night). Will they go away when the body gets used to the > > pills or do I need to ask my doctor for an alternative? I will only take > > them infrequently. >
From: REP on 17 Nov 2005 05:15 In article <0yXef.10784$fN5.2198(a)newsfe6-gui.ntli.net>, "MD" <spam(a)nospam.com> wrote: > I live in the UK. This does not appear to be available here under that name. > Any ideas if it does and what its name might be? > > > <dejanvukos71(a)yahoo.com> wrote in message > news:1131892271.371132.300390(a)f14g2000cwb.googlegroups.com... > > Hello MD, > > > > have you,maybe,tried drug called Duspatalin,especially developed for > > IBS sufferers,ie. for the spasms?Maybe you should try to talk to your > > doc about it...they say it is highly effective...it is manufactured by > > the Solvay pharmaceutical company. It's also called mebeverine. It does not seem to be available in the US; no idea if it is available in the UK or EU. BMJ. 2005 Aug 20;331(7514):435. Epub 2005 Aug 10. Related Articles, Links ?? Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial. Kennedy T, Jones R, Darnley S, Seed P, Wessely S, Chalder T. Department of General Practice and Primary Care, Guy's, King's, and St Thomas' School of Medicine, King's College, London SE11 6SP. OBJECTIVE: To assess the efficacy of cognitive behaviour therapy delivered in primary care for treating irritable bowel syndrome. DESIGN: Randomised controlled trial. SETTING: 10 general practices in London. PARTICIPANTS: 149 patients with moderate or severe irritable bowel syndrome resistant to the antispasmodic mebeverine. INTERVENTIONS: Cognitive behaviour therapy delivered by trained primary care nurses plus 270 mg mebeverine taken thrice daily compared with mebeverine treatment alone. MAIN OUTCOME MEASURES: Primary measures were patients' scores on the irritable bowel syndrome symptom severity scale. Secondary measures were scores on the work and social adjustment scale and the hospital anxiety and depression scale. RESULTS: Of 334 referred patients, 72 were randomised to mebeverine plus cognitive behaviour therapy and 77 to mebeverine alone. Cognitive behaviour therapy had considerable initial benefit on symptom severity compared with mebeverine alone, with a mean reduction in score of 68 points (95% confidence interval 103 to 33), with the benefit persisting at three months and six months after therapy (mean reductions 71 points (109 to 32) and 11 points (20 to 3)) but not later. Cognitive behaviour therapy also showed significant benefit on the work and social adjustment scale that was still present 12 months after therapy (mean reduction 2.8 points (5.2 to 0.4)), but had an inconsistent effect on the hospital anxiety and depression scale. CONCLUSION: Cognitive behaviour therapy delivered by primary care nurses offered additional benefit over mebeverine alone up to six months, although the effect had waned by 12 months. Such therapy may be useful for certain patients with irritable bowel syndrome in primary care. Int J Clin Pract. 2000 Sep;54(7):461-4. Related Articles, Links Comparison of two different formulations of mebeverine hydrochloride in irritable bowel syndrome. Gilbody JS, Fletcher CP, Hughes IW, Kidman SP. Solvay Healthcare, Southampton, UK. A total of 213 patients were recruited to a multicentre, randomised, double-blind, double dummy, general practice study lasting eight weeks. The objectives of the study were (i) to demonstrate therapeutic equivalence of mebeverine hydrochloride 200 mg b.i.d. capsules (Colofac MR) and 135 mg t.i.d. tablets (Colofac) in the treatment of abdominal pain in irritable bowel syndrome (IBS) and (ii) to evaluate safety and physicians' and patients' assessments of therapeutic response. Patients were randomised at day 0 and assessments performed after four and eight weeks. Primary and secondary efficacy endpoints were number of responders (response being defined as 50% or more improvement in global mean visual analogue scale for abdominal pain); patients' and physicians' global assessment of therapeutic response; and physicians' global impression of patient symptoms. Safety was assessed from adverse event reports and routine laboratory tests. Therapeutic equivalence was proven statistically (difference < 18%; p = 0.003), with 65/92 (71%) of the 135 mg t.i.d. group and 64/92 (70%) of the 200 mg b.i.d. group classified as responders. The patients' evaluation of response (week 8) was that 75% of 135 mg t.i.d. and 81% of 200 mg b.i.d. improved; the physicians' assessment of therapeutic response (week 8) was that 64% of 135 mg t.i.d. and 70% of 200 mg b.i.d. had no or mild symptoms. In conclusion, Mebeverine hydrochloride 200 mg b.i.d. (Colofac MR) was shown to be therapeutically equivalent to mebeverine hydrochloride 135 mg t.i.d. (Colofac) in the treatment of abdominal pain in IBS. Results for the secondary efficacy variables were comparable. No safety concerns were identified. J Gastroenterol Hepatol. 2000 Aug;15(8):925-30. Related Articles, Links ? Effect of a calcium channel blocker and antispasmodic in diarrhoea-predominant irritable bowel syndrome. Lu CL, Chen CY, Chang FY, Chang SS, Kang LJ, Lu RH, Lee SD. Department of Medicine and Surgery, Taipei Veterans General Hospital and National Yang-Ming University, Taiwan. BACKGROUND: Irritable bowel syndrome (IBS) is a colonic function disorder. Both pinaverlum bromide (a selective calcium channel blocker) and mebeverine (an antispasmodic) are reported to be effective in the long-term (12-16 weeks) treatment of IBS patients. Their efficacy in the short-term treatment of IBS patients and colonic transit time is unclear. Furthermore, substance P and neuropeptide Y have either excitatory or inhibitory effects on colonic motility. Whether the efficacy of both drugs is mediated through these neuropeptides remains unknown. METHODS AND RESULTS: A clinical trial was conducted with 91 patients with diarrhoea-predominant IBS. After basal measurement of the total colonic transit time, IBS patients were randomized to receive either pinaverlum bromide (50 mg, t.i.d.) or mebeverine (100 mg, t.i.d.) for 2 weeks. The symptomatic scores regarding defaecation, total colonic transit time and serum levels of substance P and neuropeptide Y were measured before and after treatments. The daily defaecation frequency was markedly decreased after treatment (pinaverlum bromide, 2.9+/-1.2 vs 2.0+/-1.0, P< 0.05; mebeverine, 2.7+/-1.1 vs 2.1+/-1.0, P< 0.05). The stool consistency became well formed after both treatments (P< 0.05). Both drugs similarly improved the global well-being in these IBS patients (pinaverlum bromide vs mebeverine 73.4 vs 71.8%, P> 0.05). The total colonic transit time was significantly prolonged only after pinaverlum bromide treatment (21.4+/-15.5 vs 30.8+/-14.8 h, P< 0.01). Neither substance P nor neuropeptide Y serum level was significantly changed after either treatments. CONCLUSION: Pinaverlum bromide and mebeverine have similar therapeutic efficacies on diarrhoea-predominant IBS patients. Prolonged colonic transit time may be one of the factors responsible for the efficacy of pinaverlum bromide on the IBS patients. Substance P and neuropeptideY appear less important in the pathogenesis of diarrhoea-predominant IBS. -- "Did Father shoot him? I will eat Grandfather for dinner." - Helen Keller, on learning of the death of her grandfather
From: MD on 17 Nov 2005 06:10
Thanks. It does appear to be available in the UK according to www.netdoctor.co.uk under the name Colofac. "REP" <rep(a)inanna.com> wrote in message news:LKYef.16381$7h7.14327(a)newssvr21.news.prodigy.com... > In article <0yXef.10784$fN5.2198(a)newsfe6-gui.ntli.net>, > "MD" <spam(a)nospam.com> wrote: > > > I live in the UK. This does not appear to be available here under that name. > > Any ideas if it does and what its name might be? > > > > > > <dejanvukos71(a)yahoo.com> wrote in message > > news:1131892271.371132.300390(a)f14g2000cwb.googlegroups.com... > > > Hello MD, > > > > > > have you,maybe,tried drug called Duspatalin,especially developed for > > > IBS sufferers,ie. for the spasms?Maybe you should try to talk to your > > > doc about it...they say it is highly effective...it is manufactured by > > > the Solvay pharmaceutical company. > > It's also called mebeverine. It does not seem to be available in the US; > no idea if it is available in the UK or EU. > > BMJ. 2005 Aug 20;331(7514):435. Epub 2005 Aug 10. > Related Articles, Links > > Cognitive behaviour therapy in addition to antispasmodic treatment for > irritable bowel syndrome in primary care: randomised controlled trial. > > Kennedy T, Jones R, Darnley S, Seed P, Wessely S, Chalder T. > > Department of General Practice and Primary Care, Guy's, King's, and St > Thomas' School of Medicine, King's College, London SE11 6SP. > > OBJECTIVE: To assess the efficacy of cognitive behaviour therapy > delivered in primary care for treating irritable bowel syndrome. DESIGN: > Randomised controlled trial. SETTING: 10 general practices in London. > PARTICIPANTS: 149 patients with moderate or severe irritable bowel > syndrome resistant to the antispasmodic mebeverine. INTERVENTIONS: > Cognitive behaviour therapy delivered by trained primary care nurses > plus 270 mg mebeverine taken thrice daily compared with mebeverine > treatment alone. MAIN OUTCOME MEASURES: Primary measures were patients' > scores on the irritable bowel syndrome symptom severity scale. Secondary > measures were scores on the work and social adjustment scale and the > hospital anxiety and depression scale. RESULTS: Of 334 referred > patients, 72 were randomised to mebeverine plus cognitive behaviour > therapy and 77 to mebeverine alone. Cognitive behaviour therapy had > considerable initial benefit on symptom severity compared with > mebeverine alone, with a mean reduction in score of 68 points (95% > confidence interval 103 to 33), with the benefit persisting at three > months and six months after therapy (mean reductions 71 points (109 to > 32) and 11 points (20 to 3)) but not later. Cognitive behaviour therapy > also showed significant benefit on the work and social adjustment scale > that was still present 12 months after therapy (mean reduction 2.8 > points (5.2 to 0.4)), but had an inconsistent effect on the hospital > anxiety and depression scale. CONCLUSION: Cognitive behaviour therapy > delivered by primary care nurses offered additional benefit over > mebeverine alone up to six months, although the effect had waned by 12 > months. Such therapy may be useful for certain patients with irritable > bowel syndrome in primary care. > > Int J Clin Pract. 2000 Sep;54(7):461-4. > Related Articles, Links > > Comparison of two different formulations of mebeverine hydrochloride in > irritable bowel syndrome. > > Gilbody JS, Fletcher CP, Hughes IW, Kidman SP. > > Solvay Healthcare, Southampton, UK. > > A total of 213 patients were recruited to a multicentre, randomised, > double-blind, double dummy, general practice study lasting eight weeks. > The objectives of the study were (i) to demonstrate therapeutic > equivalence of mebeverine hydrochloride 200 mg b.i.d. capsules (Colofac > MR) and 135 mg t.i.d. tablets (Colofac) in the treatment of abdominal > pain in irritable bowel syndrome (IBS) and (ii) to evaluate safety and > physicians' and patients' assessments of therapeutic response. Patients > were randomised at day 0 and assessments performed after four and eight > weeks. Primary and secondary efficacy endpoints were number of > responders (response being defined as 50% or more improvement in global > mean visual analogue scale for abdominal pain); patients' and > physicians' global assessment of therapeutic response; and physicians' > global impression of patient symptoms. Safety was assessed from adverse > event reports and routine laboratory tests. Therapeutic equivalence was > proven statistically (difference < 18%; p = 0.003), with 65/92 (71%) of > the 135 mg t.i.d. group and 64/92 (70%) of the 200 mg b.i.d. group > classified as responders. The patients' evaluation of response (week 8) > was that 75% of 135 mg t.i.d. and 81% of 200 mg b.i.d. improved; the > physicians' assessment of therapeutic response (week 8) was that 64% of > 135 mg t.i.d. and 70% of 200 mg b.i.d. had no or mild symptoms. In > conclusion, Mebeverine hydrochloride 200 mg b.i.d. (Colofac MR) was > shown to be therapeutically equivalent to mebeverine hydrochloride 135 > mg t.i.d. (Colofac) in the treatment of abdominal pain in IBS. Results > for the secondary efficacy variables were comparable. No safety concerns > were identified. > > J Gastroenterol Hepatol. 2000 Aug;15(8):925-30. > Related Articles, Links > > Effect of a calcium channel blocker and antispasmodic in > diarrhoea-predominant irritable bowel syndrome. > > Lu CL, Chen CY, Chang FY, Chang SS, Kang LJ, Lu RH, Lee SD. > > Department of Medicine and Surgery, Taipei Veterans General Hospital and > National Yang-Ming University, Taiwan. > > BACKGROUND: Irritable bowel syndrome (IBS) is a colonic function > disorder. Both pinaverlum bromide (a selective calcium channel blocker) > and mebeverine (an antispasmodic) are reported to be effective in the > long-term (12-16 weeks) treatment of IBS patients. Their efficacy in the > short-term treatment of IBS patients and colonic transit time is > unclear. Furthermore, substance P and neuropeptide Y have either > excitatory or inhibitory effects on colonic motility. Whether the > efficacy of both drugs is mediated through these neuropeptides remains > unknown. METHODS AND RESULTS: A clinical trial was conducted with 91 > patients with diarrhoea-predominant IBS. After basal measurement of the > total colonic transit time, IBS patients were randomized to receive > either pinaverlum bromide (50 mg, t.i.d.) or mebeverine (100 mg, t.i.d.) > for 2 weeks. The symptomatic scores regarding defaecation, total colonic > transit time and serum levels of substance P and neuropeptide Y were > measured before and after treatments. The daily defaecation frequency > was markedly decreased after treatment (pinaverlum bromide, 2.9+/-1.2 vs > 2.0+/-1.0, P< 0.05; mebeverine, 2.7+/-1.1 vs 2.1+/-1.0, P< 0.05). The > stool consistency became well formed after both treatments (P< 0.05). > Both drugs similarly improved the global well-being in these IBS > patients (pinaverlum bromide vs mebeverine 73.4 vs 71.8%, P> 0.05). The > total colonic transit time was significantly prolonged only after > pinaverlum bromide treatment (21.4+/-15.5 vs 30.8+/-14.8 h, P< 0.01). > Neither substance P nor neuropeptide Y serum level was significantly > changed after either treatments. CONCLUSION: Pinaverlum bromide and > mebeverine have similar therapeutic efficacies on diarrhoea-predominant > IBS patients. Prolonged colonic transit time may be one of the factors > responsible for the efficacy of pinaverlum bromide on the IBS patients. > Substance P and neuropeptideY appear less important in the pathogenesis > of diarrhoea-predominant IBS. > > -- > "Did Father shoot him? I will eat Grandfather for dinner." > - Helen Keller, on learning of the death of her grandfather |